Published in Cancer Weekly, August 18th, 1997
Although adoptive immunotherapy with T cells and exogenous IL-2 represents an important therapeutic avenue for patients with advanced disease, its results still remain unsatisfactory. Active immunization with autologous or allogeneic melanoma cells is an intriguing immunotherapeutic approach.
Research has shown that a) melanoma antigens exist that are recognized by T cells and that these genes can be cloned (T. Boon et al., J. Exp Med 1996;183:725); b) melanoma-specific T cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.